Taysha Gene Therapies Price to Free Cash Flow Ratio 2020-2023 | TSHA
Historical price to free cash flow ratio values for Taysha Gene Therapies (TSHA) since 2020.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Taysha Gene Therapies Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2024-04-26 |
2.39 |
|
0.00 |
| 2023-12-31 |
1.77 |
$-0.66 |
0.00 |
| 2023-09-30 |
3.16 |
$0.00 |
0.00 |
| 2023-06-30 |
0.66 |
$-0.89 |
0.00 |
| 2023-03-31 |
0.80 |
$-1.57 |
0.00 |
| 2022-12-31 |
2.26 |
$-2.48 |
0.00 |
| 2022-09-30 |
1.93 |
$-4.28 |
0.00 |
| 2022-06-30 |
3.72 |
$-4.48 |
0.00 |
| 2022-03-31 |
6.52 |
$-4.20 |
0.00 |
| 2021-12-31 |
11.65 |
$-3.52 |
0.00 |
| 2021-09-30 |
18.62 |
$-3.02 |
0.00 |
| 2021-06-30 |
21.20 |
$-3.04 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.430B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
